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Abstract 
Primary progressive multiple sclerosis (MS) differs from the more common form of MS which has an 
initial relapsing–remitting course in a number of ways, including pathological features, clinical course, 
differential diagnosis and response to treatment. The lesions in primary progressive MS tend to be more 
diffuse, less inflammatory and less likely to remyelinate than those occurring in relapsing–remitting MS 
and secondary progressive MS; there are also fewer focal lesions in the brain in primary progressive MS. 
Recent evidence suggests that antibodies to central nervous system (CNS) antigens have an important role 
in disease progression. Such antibodies could cause demyelination, inhibit remyelination and cause axonal 
destruction. Ongoing immune attack by autoantibody and lack of CNS repair could be responsible for the 
gradually increasing disability in primary progressive MS. Further research on the B-cell and autoantibody 
response in primary progressive MS might lead to advances in diagnosis and treatment. Inhibition of 
autoantibody production by inducing B-cell apoptosis with rituximab is a potential new therapy for primary 
progressive MS. 
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Introduction 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system 
(CNS) that almost certainly has an autoimmune basis. Most patients with MS have an initial relapsing–
remitting course with attacks of neurological impairment followed by clinical recovery and intervals 
without  deterioration. The majority of patients with an initial relapsing–remitting course eventually enter a 
phase of progressive clinical deterioration with or without superimposed relapses (secondary progressive 
MS). Some people with MS have progressive clinical deterioration from onset (primary progressive MS); 
most of these patients do not experience relapses but 28% have a relapse at some stage.1 Primary 
progressive MS differs from relapsing–remitting and secondary progressive MS not only in clinical course 
but also in pathological features, differential diagnosis and response to treatment. This review will focus on 
the pathogenesis of primary progressive MS and its implications for understanding and improving 
diagnosis and treatment. 
 
Clinical Features And Diagnosis Of Primary Progressive Ms 
Primary progressive MS tends to have a later age of clinical onset (mean ~39 years), typically about 10 
years later, than relapsing–remitting MS.1, 2 Interestingly, a recent case report of the clinical presentation of 
primary progressive MS 10 years after the incidental finding of typical magnetic resonance imaging (MRI) 
brain lesions raises the possibility that the CNS lesions may actually have a similar age of onset as in 
relapsing–remitting MS.3 The female to male ratio in primary progressive MS (1.3:1.0) is lower than in 
relapsing–remitting MS.1, 2 Progressive paraparesis is the most common presentation of primary 
progressive MS;4 progressive visual loss may be the presenting feature but is uncommon. 2, 5, 6 Irreversible 
disability occurs sooner after clinical onset in primary progressive MS than in patients with an initial 
relapsing–remitting course.7 In contrast, once irreversible disability occurs, the time course of progressive 
disability is similar in primary progressive and secondary progressive MS.7 
 Primary progressive MS is more difficult to diagnose than relapsing–remitting MS for the 
following reasons: (1) in contrast to the relapsing–remitting pattern which occurs in few neurological 
diseases other than MS, the progressive neurological deterioration over months and years that occurs in 
primary progressive MS is also typical of many other neurological diseases; (2) the variety of neurological 
symptoms and signs occurring in primary progressive MS tends to be more limited than in relapsing–
remitting MS, and this also reduces the distinctiveness of the clinical features; (3) there are fewer MRI 
focal brain lesions 8, 9 and less frequent gadolinium-enhancing brain lesions10 in primary progressive MS 
than in relapsing–remitting / secondary progressive MS; and (4) oligoclonal immunoglobulin (Ig) bands 
restricted to the cerebrospinal fluid (CSF) occur less frequently in male patients with a later onset and 
progressive myelopathy,11 that is the type of patient likely to have primary progressive MS. New diagnostic 
criteria have recently been proposed for definite primary progressive MS;12, 13 however, the absolute 
requirement for evidence of intrathecal IgG synthesis will significantly reduce the diagnostic sensitivity. 
 
Genetics Of Primary Progressive Ms 
There is an increased occurrence of other autoimmune diseases in patients with MS and in their first-degree 
relatives, suggesting that individuals with MS have a genetic predisposition to autoimmunity in general.14 
This applies at least as often to patients with primary progressive MS as to those with relapsing–remitting 
or secondary progressive MS.14 It has been hypothesized that this genetic susceptibility results in a failure 
of activation-induced apoptosis of autoreactive T lymphocytes in the CNS 15 because these T cells receive 
survival signals from B lymphocytes harbouring the Epstein–Barr virus.16 Different class II major 
histocompatibility complex (MHC) genes are associated with different autoimmune diseases, probably 
because they determine which self antigens and therefore which organs are targeted. MS is associated with 
the HLA-DRB1*1501-DQA1*0102-DQB1*0602 haplotype. 17 This haplotype occurs at a similar 
frequency in primary progressive MS, relapsing–remitting MS and secondary progressive MS; however, 
patients with primary progressive MS are more likely to have a DR6 haplotype combined with this 
haplotype.18 Such a difference in MHC expression could result in different CNS antigens being targeted by 
the immune system and consequent differences in CNS repair and disease progression. Other genes may 
also influence the course of MS by exerting a modulatory effect on the immune response. A recent study 
found that a particular polymorphism of the cytotoxic T-lymphocyte antigen 4 (CTLA4) gene, which 
downregulates T-cell function, is associated with primary progressive MS.19 
 
Possible Mechanisms Of Relapse And Progression 
A relapse differs from progression in that the clinical deterioration during a relapse is usually more rapid, 
of limited duration and reversible, whereas the clinical deterioration during progression is slower, 
prolonged or indefinite, and not reversible. The degree of neurological impairment is the outcome of a 
dynamic relationship between immune attack on the nervous system and repair of the nervous system. 
 
Relapse 
Relapses are likely to be due to episodes of immune attack on CNS myelin by T cells with or without 
antibody, followed by remyelination leading to repair and clinical recovery. In chronic relapsing 
experimental autoimmune encephalomyelitis (EAE), an animal model of MS, relapses are characterized by 
inflammatory cell infiltration and primary demyelination, whereas remissions are characterized by 
resolution of inflammation and by remyelination. 20 Clinical relapses of MS are associated with an increase 
in the number and extent of gadolinium-enhancing lesions,21 which correlate with perivascular 
inflammation.22 Patients with relapsing–remitting MS have surges of increased numbers of circulating 
myelin-reactive T lymphocytes which partly correlate with the number of gadolinium-enhancing brain 
lesions.23 Thus, attacks of MS might be due to episodes of T cell attack on CNS myelin. The presence of 
antimyelin antibody will increase the extent of demyelination and the severity of the neurological deficit, as 
it does in EAE.24 The combination of T cells and antibody is commonly present in active demyelinating 
lesions in MS.25 Remyelination occurs in the CNS in MS26 and is likely to contribute to clinical recovery, 
as it does in EAE.27 
 
Progression 
Progression of neurological impairment could be due to two mechanisms. First, it could be due to a rapid 
and relentless immune attack on CNS myelin and axons by T cells and antibody; this might be the 
mechanism in the rarely occurring acute MS (Marburg’s disease) and will not be discussed further. Second, 
it could be due to a prolonged slow immune attack on myelin and axons without CNS repair; this might be 
the mechanism in primary and secondary progressive MS. A prolonged slow immune attack on the CNS is 
more likely to occur when antibodies, rather than T cells, constitute the main mechanism of attack because 
circulating antigen-specific antibody levels remain persistently elevated as opposed to the marked 
fluctuations that occur in the levels of circulating antigen-specific T cells. A failure of CNS repair could 
occur because of immune attack preventing remyelination or because of immune-mediated destruction of 
axons, which cannot regenerate in the human CNS. Antibodies are more likely than T cells to be effective 
inhibitors of remyelination because of their persistence and ability to spread diffusely through the CNS 
parenchyma. Thus, progression in primary and secondary progressive MS might be due to a predominantly 
antibody-mediated immune attack that causes demyelination and inhibits remyelination or that causes 
axonal destruction. Relapses superimposed on a primary progressive course might be due to episodes of T-
cell immune attack on the CNS with or without CNS repair. 
 
Pathogenesis Of Primary Progressive MS 
 
Inflammation 
Gadolinium-enhancing MRI brain lesions occur much less frequently in primary progressive MS than in 
secondary progressive MS10 and relapsing–remitting MS,21 indicating that there is less inflammation in the 
brain in primary progressive MS. Histological studies have shown less perivascular lymphocytic cuffing 
and parenchymal inflammatory cell infiltration in the CNS in primary progressive MS than in secondary 
progressive MS.28 Immunological studies have shown increased blood T-cell reactivity to the 184–209 
region of myelin proteolipid protein in relapsing–remitting MS and secondary progressive MS, but not in 
primary progressive MS,29 although T-cell reactivity to the gangliosides GM3 and GQ1b is increased in 
primary progressive MS.30 Furthermore, blood leukocyte expression of adhesion molecules, which have a 
role in the trafficking of circulating leukocytes into the CNS, is different between primary progressive MS 
and relapsing– remitting/secondary progressive MS.31 
 
Antibody 
Recent evidence indicates that an increased CSF B cell to monocyte ratio correlates with disease 
progression in MS 32 and that the presence of intrathecal IgM synthesis in relapsing–remitting MS predicts 
secondary progression.33 These findings raise the possibility that disease progression is related to antibody-
mediated CNS damage. Patients with primary progressive MS have increased serum antiganglioside 
antibody levels compared to those with relapsing–remitting MS and controls; 34, 35 the levels in secondary 
progressive MS tend to be intermediate between those in primary progressive MS and relapsing–remitting 
MS.35 Furthermore, antibodies to light neurofilament subunit, an axonal cytoskeletal protein, are increased 
in the CSF in primary and secondary progressive MS compared to relapsing–remitting MS.36 Antibodies to 
CNS antigens could contribute to progression by causing demyelination or axonal damage or by inhibiting 
remyelination. Further definition of these antibodies might lead to advances in the diagnosis 
and prognosis of primary progressive MS. 
 
Neuronal damage 
Hypointense lesions (‘black holes’) on T1-weighted MRI brain imaging correlate with severe tissue 
destruction, including axonal loss, 37 and their rate of accumulation correlates with rate of disease 
progression in secondary progressive MS.38 However, hypointense T1 brain lesions occur much less 
frequently in primary progressive MS than in secondary progressive MS and no more frequently than in 
relapsing–remitting MS.39 Furthermore, histological studies indicate that acute axonal injury occurs less 
frequently in the focal lesions of primary progressive MS and relapsing–remitting MS than in the focal 
lesions of secondary progressive MS.40 Therefore, if axonal damage has a major role in causing 
neurological impairment in primary progressive MS, it might be occurring diffusely rather than focally. 
Although the total brain white matter focal lesion load is considerably lower in primary progressive MS 
than in secondary progressive MS,8, 39 diffuse lesions on T2-weighted and proton density-weighted imaging 
occur more commonly in the brain and spinal cord in primary progressive MS than in secondary 
progressive MS.39 Furthermore, magnetization transfer imaging in primary progressive MS has revealed the 
presence of diffuse tissue damage undetectable by conventional MRI, the extent of which matches that of 
patients with secondary progressive MS with similar levels of disability.41 The contribution of cerebral 
cortical damage to neurological impairment in MS also needs to be considered. Conventional MRI is 
insensitive for detecting cortical lesions but automated analysis has shown cerebral cortical atrophy in 
primary progressive MS despite minimal white matter lesion accumulation.42 Cerebral cortical lesions in 
MS are characterized by demyelination, axonal transection, dendritic transection, neuronal apoptosis and 
reduced inflammation compared to white matter lesions.43 It remains to be determined to what extent 
cerebral cortical damage contributes to disease progression in primary progressive MS. 
 
Remyelination 
Demyelinated lesions without oligodendrocyte recruitment or remyelination occur more frequently in 
primary progressive MS than in relapsing–remitting MS and secondary progressive MS.44 In three cases of 
primary progressive MS, the demyelination in such lesions has been associated with oligodendrocyte death 
in a small rim of periplaque white matter, adjacent to the zone of active myelin destruction.25 The lack of 
remyelination raises the possibility that immune attack might prevent remyelination in primary progressive 
MS and that demyelination without remyelination could be an important mechanism for disease 
progression. One possible immune mechanism for inhibiting remyelination is the action of antiGM3 
antibodies which are elevated in the sera of patients with primary progressive MS; 35 these antibodies might 
interfere with the important role that GM3 ganglioside has in the differentiation of oligodendrocyte 
progenitors toward myelin production.45 
 
Spinal cord involvement 
Whereas the MRI focal lesion load in the brain in primary progressive MS is lower than in relapsing–
remitting MS and secondary progressive MS,8, 9 the focal lesion load in the spinal cord does not differ 
significantly among these forms.9 Thus, a higher proportion of the total MRI lesion load is in the spinal 
cord in primary progressive MS.9 However, it should be noted that the lesion load in the spinal cord 
compared to the brain is low in all forms of MS and therefore might not be as sensitive in detecting 
differences among the different forms. Some patients with primary progressive MS have spinal cord 
involvement but minimal or no brain lesions on MRI.46 Longitudinal MRI studies have shown that new 
lesions accumulate in the spinal cord at the same rate in primary and secondary progressive MS although 
the rate of new lesion development in the brain is much lower in primary than in secondary progressive 
MS.47 Diffuse MRI abnormalities are more common in the spinal cord, as they are in the brain, in primary 
progressive MS compared to relapsing–remitting MS and secondary progressive MS.39 Spinal cord atrophy, 
determined by measuring spinal cord cross-sectional area on T1-weighted imaging, occurs in primary 
progressive MS, as in the other forms of MS.9 The cross-sectional area at the C2 level has a strong inverse 
correlation with disability measured by Kurtzke’s Expanded Disability Status Scale when all MS patients 
are grouped together,48 but not within the primary progressive group.39 
 
Treatment Of Primary Progressive Ms 
Currently there is no effective treatment for primary progressive MS. Interferon β-1b and interferon β-1a 
make primary progressive MS worse, as manifested by increased spasticity 49 and an increased rate of 
ventricular enlargement,50 possibly by inhibiting B-lymphocyte apoptosis and increasing antibody-mediated 
CNS damage.51 The development of effective therapy for primary progressive MS will be dependent on a 
better understanding of the pathogenesis. It has been proposed that depletion of B cells by rituximab may 
be beneficial in MS and other chronic autoimmune diseases.16 Such B-cell depletion might be effective by 
preventing antigen presentation to T cells in the CNS and by preventing autoantibody production. 
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